We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Piracetam
First-ever nootropic (1972); improves membrane fluidity and AMPA receptor function and has decades of safety data, though recent meta-analyses find no clear cognitive benefit in healthy adults.
Research compound — not a dietary supplement
Piracetam is a research compound, not a regulated dietary supplement. It is sold for research or off-label use. The evidence below is largely preclinical (animal and in-vitro) or early-stage, so no evidence score is assigned. This page is provided for transparency and education — it is not a recommendation to use. Consult a qualified healthcare provider, and be aware that purity, dosing, and legal status vary by jurisdiction.
What the evidence says
Piracetam appears to help in 3 of 4 studies with measurable effects — the evidence leans clearly favourable.
Most evidence is from high-quality meta-analyses and randomised trials published 1976–2026 with a typical study size of 243 participants.
Based on 108 studies · 12 meta-analyses · 88 RCTs · 59,800 total participants
Confidence
High confidenceWhat the studies found
By outcome
Scores low/Emerging because despite decades of trials and a strong safety record, recent meta-analyses find no clinically significant cognitive benefit in healthy adults, with positive signals confined to clinical populations.
107 rigorous studies
89 randomized trials · 10 meta-analyses · 8 systematic reviews
Our evidence rating for Piracetam is accountable to this entire body of rigorous research indexed in PubMed — not a hand-picked subset.
PubMed · as of Jul 2026
3 trials ongoing or recruiting · 7 completed on ClinicalTrials.gov
Registered trials show research momentum for Piracetam, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Aug 2026
Piracetam was the first compound classified as a 'nootropic' by Dr. Corneliu Giurgea in 1972. It enhances cognitive function through multiple mechanisms including improved membrane fluidity, modulation of AMPA receptors, and enhanced cholinergic neurotransmission.
It's particularly noted for benefits in elderly cognitive decline and has been studied for decades with a strong safety profile. Best effects are often seen when combined with a choline source.
Positive allosteric modulator of AMPA receptors
Improves neuronal membrane flexibility
Increases acetylcholine activity
How Piracetam works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Well-studied population; may see greatest benefits
Piracetam is cleared unchanged by the kidneys; reduce dose in mild-to-moderate impairment and avoid in severe impairment
Piracetam has antiplatelet activity and may add to the effects of warfarin, antiplatelet agents, or other anticoagulants, increasing bleeding risk — monitor
Tip: Take with choline source (Alpha-GPC, CDP-Choline)
Tip: Avoid evening doses
Piracetam has an evidence score of 4.5/10 — emerging evidence based on 28 indexed studies, including 9 meta-analyses. First-ever nootropic (1972); improves membrane fluidity and AMPA receptor function and has decades of safety data, though recent meta-analyses find no clear cognitive benefit in healthy adults. Representative study: PMID 29502274.
The commonly studied dose of Piracetam is 1200-4800mg daily in divided doses. Research points to an estimated optimal dose around 2400mg, with a minimum effective dose near 1200mg. Individual response varies — start low and adjust.
The best time to take Piracetam is in split doses through the day. Taking it with food is preferred. Piracetam is the prototypical racetam nootropic that modulates AMPA receptors and enhances membrane fluidity.
Piracetam is generally well-tolerated and considered safe for most healthy adults at recommended doses. The most commonly reported side effects are headache, insomnia. Use caution if any of these apply to you: Severe kidney impairment (excreted renally); Huntington's disease (theoretical concern).
Huperzine A
Likely helpsAcetylcholinesterase inhibitor from club moss, studied mainly for Alzheimer's and dementia; cognitive evidence is mixed and limited by trial quality.
Noopept
Mostly mechanism / observationalSynthetic peptide ~1,000x more potent than piracetam; studied for memory and learning, with limited controlled human data.
Alpha-GPC
Likely helpsCrosses the blood-brain barrier to fuel acetylcholine synthesis — supports focus, memory, and power output in athletes.
Citicoline
Probably helpsDual precursor to acetylcholine and phosphatidylcholine — enhances memory, focus, and brain cell membrane repair.
Explore: Best supplements for Focus, Memory & MoodBest supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed May 2026 · evidence from 108 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research